Generation Bio Co. (GBIO) Stock Analysis & Investment Frameworks
Generation Bio Co. (GBIO) stock analysis on Invetso. Review Generation Bio Co.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Generation Bio Co. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Generation Bio Co. Key Financial Metrics
- Market Cap: $35.98M
- Revenue: $19.89M
- ROE: -50.53%
- ROIC: -41.43%
- Dividend Yield: N/A
About Generation Bio Co.
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.